Fig. 1
From: RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer
RASON is essential for KRAS-driven lung tumorigenesis in mice and is highly expressed in NSCLC patients. A-D, RASON knockout suppressed KRAS-driven lung tumorigenesis in LSL-KrasG12D; LSL-Trp53R172H/+ (KP) mice. A, Representative micro-CT images and H&E-stained lung tissue sections from KP and KPR (KP mice with Rason knockout) mice (n = 6 for KP, n = 4 for KPR, scale bar, 2 mm). B, Representative images of lungs from KP and KPR mice. Black circles indicate lung tumor. Scale bar, 1 cm. C, Quantification of lung tumor areas in KP and KPR mice. D, Kaplan-Meier survival curve analysis of KP and KPR mice (n = 12 for KP, n = 10 for KPR). E-K, RASON expression is elevated in a tissue microarray of 80 human NSCLC samples. E, Representative IHC images of RASON staining in NSCLC tumor tissues and adjacent normal tissues. Scale bar, 50 μm. F, Dot plot showing quantified H-scores for RASON expression. G, Representative IHC images showing RASON expression in NSCLC samples across different tumor stages. Scale bar, 50 μm. H, Dot plot showing H-score of RASON expression for KRASmut NSCLC samples (n = 44) stratified by tumor stages. I, Dot plot showing H-score of RASON expression for KRASmut NSCLC samples stratified by combined stages. J, Correlation analysis of RASON expression and CD11b levels in KRASmut NSCLC samples. K, Kaplan–Meier survival analysis of KRASmut NSCLC patients stratified into high and low RASON expression groups based on H-scores (n = 20 for the RASON-low group, n = 24 for the RASON-high group). Data are shown as mean ± S.E.M. and analyzed by Student’s t-test (C, F, I) or one-way ANOVA (H). * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001